Compare Ascendis Pharma A/S (ASND) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Las Vegas Sands Corp. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Las Vegas Sands Corp. trades at $46.72 (market cap $30.94B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.36% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LVS | |
|---|---|---|
Market Cap | $17.74B | $30.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $69.49 |
52-Week Low | $163.32 | $46.06 |
Enterprise Value | $18.11B | $43.33B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LVS trades at $46.69, up 0.52% with a bearish technical signal despite strong fundamentals. The company demonstrates robust revenue growth, reaching $13.02B in 2025 with consistent earnings beats and a 13.41% net margin. Analyst consensus remains strongly bullish with a $66.89 price target, though technical indicators show selling pressure with support at $46.
LVS presents a compelling investment case with strong operational performance and analyst support, though technical weakness and high debt levels pose risks. The stock offers significant upside potential from current levels if fundamental strength continues, but investors should monitor debt management and Macau market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
